Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional Analysis
The DOI matches its Crossref record.
Abstract
PURPOSE: In a multi-institutional setting we studied the efficacy and safety outcomes at multiple high volume centers where collagenase Clostridium histolyticum is used to treat Peyronie's disease. MATERIALS AND METHODS: We collected retrospective data on consecutive patients with Peyronie's disease who underwent treatment with collagenase C. histolyticum between April 2014 and March 2018 at a total of 5 institutions. Included in the study were 918 patients. Main outcomes of interest included the change in curvature after receiving collagenase C. histolyticum therapy and the frequency of serious treatment related adverse events. The 2-tailed paired Student t-test was used to compare continuous variables. Univariate and multivariate regression analyses were performed to assess predictors of the success of collagenase C. histolyticum therapy to improve curvature. RESULTS: In the cohort of 918 patients curvature improved from a mean of 48.2 degrees before treatment to 32.9 degrees after treatment, a 30.1% improvement from baseline (p <0.0001). Of the men 68.7% had a 20% or greater improvement in curvature. In the 502 patients who completed 4 or more cycles curvature improved from a mean of 49.7 degrees before to 32.7 degrees after treatment, a 33% improvement from baseline (p <0.0001). Of these men 74.4% experienced a 20% or greater improvement in curvature. A complication of treatment developed in 9% of patients. The number of cycles of collagenase C. histolyticum received was predictive of curvature improvement (p <0.0001). CONCLUSIONS: This large multi-institutional analysis confirms the safety and efficacy of collagenase C. histolyticum therapy in men with Peyronie's disease. Intralesional collagenase C. histolyticum for Peyronie's disease according to the IMPRESS (Investigation of Maximal Peyronie's Reduction Efficacy and Safety Studies) trial protocol produced an improvement in penile curvature in men with Peyronie's disease with a low rate of complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Peyronie’s disease: pharmacological treatments and limitations
Li, E. V., Esterquest, R., Pham, M. N., Panken, E. J., Amarasekera, C., Siebert, A., Bajic, P., & Levine, L. A. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1903873 · Cited by 24
Conservative Therapy for Peyronie’s Disease: a Contemporary Review of the Literature
Yousif, A., Natale, C., & Hellstrom, W. J. G. (2021) · Current Urology Reports · doi:10.1007/s11934-020-01024-8 · Cited by 12
Self-citationCurrent trends in non‐surgical management of Peyronie's disease—A narrative review
Kozub, A., Suleja, A., Chłosta, M., Kupilas, A., Pradere, B., Rivas, J. G., Rajwa, P., & Miszczyk, M. (2024) · Andrology · doi:10.1111/andr.13512 · Cited by 5
Metadata
- Authors
- Hellstrom, W. J. G., Tue Nguyen, H. M., Alzweri, L., Chung, A., Virasoro, R., Tapscott, A., Ziegelmann, M., Trost, L., & Gelbard, M.
- Venue
- Journal of Urology
- Published
- 2019-04
- Volume
- 201
- Issue
- 4
- Pages
- 777-782
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2910192001
- Cited by
- 38
- References
- 0
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional Analysis. https://app.cochat.ai/papers/10.1097/ju.0000000000000032
- The paper
- Hellstrom, W. J. G., Tue Nguyen, H. M., Alzweri, L., Chung, A., Virasoro, R., Tapscott, A., Ziegelmann, M., Trost, L., & Gelbard, M. (2019). Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional Analysis. Journal of Urology. https://doi.org/10.1097/ju.0000000000000032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.